About Signum

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from our phosphatase platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer's, Parkinson's, and other neurodegenerative diseases. Signum's phosphatase technology provides many opportunities for the development of novel pharmaceutical therapeutics.

The Signum Difference

• Signum targets hyperphosphorylation of tau in disease
• Signum focuses on PP2A – a master regulator of cellular function
• Signum utilizes its proprietary Phosphatase platform to identify novel, effective and safe therapeutics